May 11, 2020 2:08pm

Regenerative Medicine Earnings listing for Q1/20  

My focus is to define the net income or loss, the per share amounts commonly an LPS (loss-per-share), cash positions (EOQ – “end-of-quarter”) and the “runway” of continuing operations.


Schedule for the LPS (loss-per-share) earnings of Q1/2020 of my 35 covered companies:

4/28 – CRISPR Therapeutics (CRSP) - announced

4/29 – uniQure NV (QURE) - announced


Coming attractions or LPS (loss-per-share) viewings

5/4 - Aduro Biotech (ADRO) - announced

5/5 - Vericel (VCEL) - announced

5/6 - AxoGen (AXGN), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Precigen (PGEN), Global Blood Therapeutics (GBT), Voyager Therapeutics (VYGR), Ultragenyx Pharmaceuticals (RARE);

5/7 - Athersys (ATHX), Brainstorm Cell Therapeutics (BCLI), Cellectis SA (CLLS), Sage Sherapeutics (SAGE), Caladrius Biosciences (CLBS), Intellia Therapeutics (NTLA);

5/11 - bluebird bio (BLUE), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE)

5/13 - Applied Genetic Technologies (AGTC)

5/14 - BioLife Solutions (BLFS)